KERRY COX: Open Payments
NPI 1992477632 · ROY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$898 in 52 payments from 20 companies in 2025. Trend: 2023 $1,672 · 2024 $2,348 · 2025 $898
Food & beverage: $898
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $159 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $111 |
| PFIZER INC. | 5 | $92 |
| ABBVIE INC. | 4 | $79 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| SANOFI-AVENTIS U.S. LLC | 2 | $43 |
| Astellas Pharma US Inc | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
Products named: TRELEGY ELLIPTA, CAPLYTA, NURTEC ODT, VRAYLAR, Auvelity, TZIELD, Veozah, PREVNAR 20.
Industry payments across UT — which companies pay providers there.
